Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 4/2005

01.08.2005 | Review

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer

verfasst von: Barry A Gusterson, Douglas T Ross, Victoria J Heath, Torsten Stein

Erschienen in: Breast Cancer Research | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Recent publications have classified breast cancers on the basis of expression of cytokeratin-5 and -17 at the RNA and protein levels, and demonstrated the importance of these markers in defining sporadic tumours with bad prognosis and an association with BRCA1-related breast cancers. These important observations using different technology platforms produce a new functional classification of breast carcinoma. However, it is important in developing hypotheses about the pathogenesis of this tumour type to review the nomenclature that is being used to emphasize potential confusion between terminology that defines clinical subgroups and markers of cell lineage. This article reviews the lineages in the normal breast in relation to what have become known as the 'basal-like' carcinomas.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Behbod F, Rosen JM: Will cancer stem cells provide new therapeutic targets?. Carcinogenesis. 2004, 26: 703-711. 10.1093/carcin/bgh293.CrossRefPubMed
2.
Wilson CA, Dering J: Recent translational research: microarray expression profiling of breast cancer – beyond classification and prognostic markers?. Breast Cancer Res. 2004, 6: 192-200. 10.1186/bcr917.CrossRefPubMedPubMedCentral
3.
Anbazhagan R, Osin PP, Bartkova J, Nathan B, Lane B, Gusterson BA: The development of epithelial phenotypes in the human fetal and infant breast. J Pathol. 1998, 184: 197-206. 10.1002/(SICI)1096-9896(199802)184:2<197::AID-PATH992>3.3.CO;2-A.CrossRefPubMed
4.
Gusterson BA, Warburton MJ, Mitchell D, Ellison M, Neville AM, Rudland PS: Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast disease. Cancer Res. 1982, 42: 4763-4770.PubMed
5.
Gusterson BA, Monaghan P, Mahendran R, Ellis J, O'Hare MJ: Identification of myoepithelial cells in human and rat breasts by anti-common acute lymphoblastic leukaemia antigen antibody A12. J Natl Cancer Inst. 1986, 77: 343-349.PubMed
6.
Moll R, Franke WW, Schiller DL: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982, 31: 11-24. 10.1016/0092-8674(82)90400-7.CrossRefPubMed
7.
Moll R, Krepler R, Frank WW: Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation. 1983, 23: 256-269.CrossRefPubMed
8.
Nagle RB, Bocker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, Jarasch ED: Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem. 1986, 34: 869-881.CrossRefPubMed
9.
Ben-Ze'ev A: Cell density and cell shape-related regulation of vimentin and cytokeratin synthesis. Exp Cell Res. 1985, 157: 520-532. 10.1016/0014-4827(85)90137-5.CrossRefPubMed
10.
Su L, Morgan PR, Lane EB: Expression of cytokeratin messenger RNA versus protein in the normal mammary gland and in breast cancer. Hum Pathol. 1996, 27: 800-806. 10.1016/S0046-8177(96)90452-9.CrossRefPubMed
11.
Wetzels RHW, Kuijpers HJH, Lane EB, Leigh IM, Troyanovsky SM, Holland R, van Haelst UJGM, Ramaekers PCS: Basal cell specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol. 1991, 138: 751-763.PubMedPubMedCentral
12.
Malzahn K, Mitze M, Thoenes M, Moll R: Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998, 433: 119-129. 10.1007/s004280050226.CrossRefPubMed
13.
Otterbach F, Bànkfalvi À, Bergner S, Decker T, Krech R, Boecker W: Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000, 37: 232-240. 10.1046/j.1365-2559.2000.00882.x.CrossRefPubMed
14.
Boecker W, Buerger H: Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif. 2003, 36: 73-84. 10.1046/j.1365-2184.36.s.1.7.x.CrossRefPubMed
15.
Smith GH, Mehrel T, Roop DR: Differential keratin gene expression in developing, differentiating, preneoplastic, and neoplastic mouse mammary epithelium. Cell Growth Differ. 1990, 1: 161-170.PubMed
16.
Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, et al: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA. 1999, 96: 12589-12594. 10.1073/pnas.96.22.12589.CrossRefPubMedPubMedCentral
17.
Wellings SR: A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathol Res Pract. 1980, 166: 515-535.CrossRefPubMed
18.
Jensen HM, Rice JR, Wellings SR: Preneoplastic lesions in the human breast. Science. 1976, 191: 295-297.CrossRefPubMed
19.
Wellings SR, Jensen HM, Marcum RG: An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975, 55: 231-273.PubMed
20.
Osin P, Shipley J, Lu YJ, Crook T, Gusterson BA: Experimental pathology and breast cancer genetics: new technologies. Recent Results Cancer Res. 1998, 152: 35-48.CrossRefPubMed
21.
Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J Pathol. 2005, 205: 248-254. 10.1002/path.1691.CrossRefPubMed
22.
Diallo R, Schaefer K-L, Poremba C, Shivazi N, Willman V, Buerger H, Dockhorn-Dworniczak B, Boecker W: Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast. J Pathol. 2001, 193: 27-32. 10.1002/1096-9896(2000)9999:9999<::AID-PATH747>3.0.CO;2-H.CrossRefPubMed
23.
O'Hare MJ, Ormerod MG, Monaghan P, Lane EB, Gusterson BA: Characterization in vitro of luminal and myoepithelial cells isolated from the human mammary gland by cell sorting. Differentiation. 1991, 46: 209-221.CrossRefPubMed
24.
Péchoux C, Gudjonsson T, Rønnov-Jessen L, Bissell MJ, Petersen OW: Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. Dev Biol. 1999, 206: 88-99. 10.1006/dbio.1998.9133.CrossRefPubMed
25.
Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ: Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol. 1988, 19: 276-289.CrossRefPubMed
26.
Böcker W, Moll R, Poremba C, Holland R, van Diest PJ, Dervan P, Bürger J, Wai D, Diallo RI, Brandt B, et al: Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002, 82: 737-745.CrossRefPubMed
27.
Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco M dM, Dale TC, Smalley MJ: Functional and molecular characerisation of mammary side population cells. Breast Cancer Res. 2002, 5: R1-R8. 10.1186/bcr547.CrossRefPubMedPubMedCentral
28.
Clayton H, Titley I, Vivanco M: Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res. 2004, 297: 444-460. 10.1016/j.yexcr.2004.03.029.CrossRefPubMed
29.
Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM, Goodell MA: Sca-1pos cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol. 2002, 245: 42-56. 10.1006/dbio.2002.0625.CrossRefPubMed
30.
Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS: A putative breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol. 2005, 277: 443-456. 10.1016/j.ydbio.2004.07.044.CrossRefPubMed
31.
Petersen OW, Gudjonsson T, Villadsen R, Bissell MJ, Rønnov-Jessen L: Epithelial progenitor cell lines as models of normal breast morphogenesis and neoplasia. Cell Prolif. 2003, 36: 33-44. 10.1046/j.1365-2184.36.s.1.4.x.CrossRefPubMedPubMedCentral
32.
Dontu G, El-Ashry D, Wicha MS: Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab. 2004, 15: 193-197. 10.1016/j.tem.2004.05.011.CrossRefPubMed
33.
Taylor-Papadimitriou J, Stampfer M, Bartek J, Lewis A, Boshell M, Lane EB, Leigh IM: Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation of in vivo phenotypes and influence of medium. J Cell Sci. 1989, 94: 403-413.PubMed
34.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
35.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
36.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral
37.
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003, 100: 10393-10398. 10.1073/pnas.1732912100.CrossRefPubMedPubMedCentral
38.
Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Karesen R, Botstein D, Borresen-Dale AL, et al: Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 2004, 15: 2523-2536. 10.1091/mbc.E03-11-0786.CrossRefPubMedPubMedCentral
39.
Ross DT, Perou CM: A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers. 2001, 17: 99-109.CrossRefPubMed
40.
Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003, 95: 1482-1485.CrossRefPubMed
41.
42.
Jones C, Nonni AV, Fulford L, Merrett S, Chaggar R, Eusebi V, Lakhani SR: CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer. 2001, 85: 422-427. 10.1054/bjoc.2001.1869.CrossRefPubMedPubMedCentral
43.
Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H: Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest. 2002, 82: 1525-1533.CrossRefPubMed
44.
Jones C, Ford E, Gillett C, Ryder K, Merrett S, Reis-Filho JS, Fulford LG, Hanby A, Lakhani SR: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res. 2004, 10: 5988-5997.CrossRefPubMed
45.
Reis-Filho JS, Milanezi F, Paredes J, Silva P, Pereira EM, Maeda SA, de Carvalho LV, Schmitt FC: Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol. 2003, 11: 1-8. 10.1097/00022744-200303000-00001.PubMed
46.
Chung CH, Bernard PS, Perou CM: Molecular portraits and the family tree of cancer. Nat Genet. 2002, 533-540. 10.1038/ng1038. Suppl
47.
Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, et al: Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004, 5: 489-500. 10.1016/S1535-6108(04)00112-6.CrossRefPubMed
48.
Nagle RB: Intermediate filaments: efficacy in surgical pathologic diagnosis. Am J Clin Pathol. 1989, 91: 14-18.
49.
Dairkee SH, Mayall BH, Smith HS, Hackett AJ: Monoclonal marker that predicts early recurrence of breast cancer. Lancet. 1987, 1: 514-CrossRefPubMed
50.
Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JFR, Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004, 203: 661-671. 10.1002/path.1559.CrossRefPubMed
51.
Van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Köchli OR, et al: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002, 161: 1991-1996.CrossRefPubMedPubMedCentral
52.
Tot T: The cytokeratin profile of medullary carcinoma of the breast. Histopathology. 2000, 37: 175-181. 10.1046/j.1365-2559.2000.00889.x.CrossRefPubMed
53.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandex-Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10: 5367-5374.CrossRefPubMed
54.
Troester MA, Hoadley KA, Sorlie T, Herbert BS, Borresen-Dale AL, Lonning PE, Shay JW, Kaufmann WK, Perou CM: Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004, 64: 4218-4226.CrossRefPubMed
Metadaten
Titel
Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer
verfasst von
Barry A Gusterson
Douglas T Ross
Victoria J Heath
Torsten Stein
Publikationsdatum
01.08.2005
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 4/2005
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1041

Weitere Artikel der Ausgabe 4/2005

Breast Cancer Research 4/2005 Zur Ausgabe

Research article

Designing a HER2/neupromoter to drive α1,3galactosyltransferase expression for targeted anti-αGal antibody-mediated tumor cell killing

Research article

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells

Research article

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2and mutation-negative breast cancer families

Research article

Alternative initiation and splicing in dicer gene expression in human breast cells

Research article

Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague–Dawley rat

Research article

Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivodetection of mammary tumors and multiple metastases in immune deficient mice

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise